ReviewWorld journal of gastroenterology2015
Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis.BMC gastroenterology · 2024Pooled it
- The effect of a plant- and dairy-based protein diet on serum levels of inflammatory and oxidative stress biomarkers in patients with liver cirrhosis: a randomized controlled trial.BMC gastroenterology · 2025Trial
- Extracellular vesicles from plasma of patients with minimal hepatic encephalopathy induce neuroinflammation and cognitive impairment in rats, which are prevented by treating the patients with rifaximin.Journal of neuroinflammation · 2026Article
- C-Reactive Protein Levels Predict Improvement in the Liver Functional Reserve by Long-Term Rifaximin Treatment.Diseases (Basel, Switzerland) · 2025Article
- A Machine Learning-Based Prognostication Model Enhances Prediction of Early Hepatic Encephalopathy in Patients With Noncancer-Related Cirrhosis: Multicenter Longitudinal Cohort Study in Taiwan.JMIR medical informatics · 2025Article
- Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies.Arquivos de neuro-psiquiatria · 2023Review
- Hypokalemia as a responsible factor related with the severity of hepatic encephalopathy: a wide multination cross-sectional study.Annals of medicine and surgery (2012) · 2023Article
- Albumin therapy for hepatic encephalopathy: current evidence and controversies.Metabolic brain disease · 2023Review
- Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation.Journal of clinical medicine · 2023Article
- Ashwagandha-loaded nanocapsules improved the behavioral alterations, and blocked MAPK and induced Nrf2 signaling pathways in a hepatic encephalopathy rat model.Drug delivery and translational research · 2023Article
- Psychometric tests, critical flicker frequency, and inflammatory indicators in covert hepatic encephalopathy diagnosis.Hepatology forum · 2023Article
- Effect of dihydromyricetin on hepatic encephalopathy associated with acute hepatic failure in mice.Pharmaceutical biology · 2021Article
- Quality of life as a therapeutic objective in the management of hepatic encephalopathy and the potential role of rifaximin-α.European journal of gastroenterology & hepatology · 2021Article
- Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis.International journal of molecular sciences · 2021Review
- Multi-omic analysis unveils biological pathways in peripheral immune system associated to minimal hepatic encephalopathy appearance in cirrhotic patients.Scientific reports · 2021Article
- The effects of concurrent treatment of silymarin and lactulose on memory changes in cirrhotic male rats.BioImpacts : BI · 2020Article
- The Role of Intestinal Bacteria and Gut-Brain Axis in Hepatic Encephalopathy.Frontiers in cellular and infection microbiology · 2020Review
- Biological Activities of Lactose-Based Prebiotics and Symbiosis with Probiotics on Controlling Osteoporosis, Blood-Lipid and Glucose Levels.Medicina (Kaunas, Lithuania) · 2018Review
- Artificial liver support systems: what is new over the last decade?Annals of intensive care · 2018Review
- Role of Peripheral Inflammation in Hepatic Encephalopathy.Journal of clinical and experimental hepatology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic encephalopathy (HE) is a severe neuropsychiatric syndrome that most commonly occurs in decompensated liver cirrhosis and incorporates a spectrum of manifestations that ranges from mild cognitive impairment to coma. Although the etiology of HE is not completely understood, it is believed that multiple underlying mechanisms are involved in the pathogenesis of HE, and one of the main factors is thought to be ammonia; however, the ammonia hypothesis in the pathogenesis of HE is incomplete. Recently, it has been increasingly demonstrated that inflammation, including systemic inflammation, neuroinflammation and endotoxemia, acts in concert with ammonia in the pathogenesis of HE in cirrhotic patients. Meanwhile, a good number of studies have found that current therapies for HE, such as lactulose, rifaximin, probiotics and the molecular adsorbent recirculating system, could inhibit different types of inflammation, thereby improving the neuropsychiatric manifestations and preventing the progression of HE in cirrhotic patients. The anti-inflammatory effects of these current therapies provide a novel therapeutic approach for cirrhotic patients with HE. The purpose of this review is to describe the inflammatory mechanisms behind the etiology of HE in cirrhosis and discuss the current therapies that target the inflammatory pathogenesis of HE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.